Minority race/ethnicity are associated with more severe outcomes in OA and RA. Although African Americans have more symptomatic RA than whites, they are more likely to delay seeking care and initiating DMARDs and biologics. The session on Nov. 6, 3 p.m. EST, will review current outcomes data for RA and OA, including TKA, THA and…
Find Solutions to Navigate Telerheumatology in Your Practice
Experts weigh in on sustaining telerheumatology as a viable practice tool by sharing its history, potential and regulatory outlook post-pandemic at ACR Convergence 2020.
ACR Convergence 2020: From Clinic to Capitol Hill Session Offers Insights into Advocacy, Regulatory Issues
Attendees at the ACR Convergence session will learn about key regulatory issues affecting rheumatology and how to add their voices to strengthen the ACR’s advocacy efforts.
ACR Urges Commercial Payers to Cover Telemedicine Beyond the Public Health Emergency
In a letter sent to commercial payers, the ACR’s Insurance Subcommittee is advocating for continued coverage for telemedicine, including reimbursement parity, after the end of the declared public health emergency.
RheumPAC Hosts Rep. Kim Schrier, MD, for Legislative Update
RheumPAC donors attended a virtual legislative update and Q&A with former pediatrician Rep. Kim Schrier, MD (D-Wash.), to gain an insider’s view of current healthcare legislation.
Nerve Growth Factor Inhibitor Study Highlights Promise as an OA Pain Treatment
A study highlights the potential of fasinumab, an anti-nerve growth factor monoclonal antibody, as a pain treatment for osteoarthritis (OA) patients. Research into the risks and benefits of this therapeutic class for OA are ongoing…
RA Patients Taking Either 15 mg or 30 mg Dose of Upadacitinib Experience Improvement
The SELECT-EARLY MTX-controlled trial examined the safety and efficacy of upadacitinib, a potent, reversible jakinib, as monotherapy in patients with moderately to highly active RA and poor prognostic features who are either naive for or have limited exposure to methotrexate.
The Environment Within: A Possible Link Identified Between Plasma Microbial Translocation & Autoantibody Development in 1st Degree Relatives of SLE Patients
Plasma microbial translocation, the composition of the microbiome and environmental factors may influence the development of autoantibodies in patients with systemic lupus erythematosus (SLE), according to a study comparing SLE patients with their first-degree relatives and unrelated, healthy controls.
State of the Art: Lupus—the Future Is Now
Sunday, Nov. 8, 2020, 10–11:00 a.m. EST: Several lupus trials this past year had positive results, bringing hope that new therapeutics may be available in the near future. This session will discuss how advances in our understanding of lupus pathogenesis have led to the development of different therapeutic strategies. Watch this page for our report…
PCSK9 Inhibitors May Lower Cholesterol in Patients with Statin-Associated Immune-Mediated Necrotizing Myopathy
A 2019 study demonstrated the benefit of a newer drug class, PCSK9 inhibitors, to help lower cholesterol in patients with statin-associated immune-mediated necrotizing myopathy…
- « Previous Page
- 1
- …
- 76
- 77
- 78
- 79
- 80
- …
- 304
- Next Page »